*** MICK, $Pistol Pete$ & FRIENDS STOCK PICKS *** M F S P''''

[$Pistol Pete$]

$NMUS Nemus Bioscience Announces License of Biosynthetic Technology from Teewinot Life Sciences to Manufacture its Proprietary Cannabinoid Molecules
ACCESSWIRE - Tue Dec 20, 6:30AM CST
COSTA MESA, CA / ACCESSWIRE / December 20, 2016 / NEMUS Bioscience, Inc. (OTCQB:NMUS) announced it has signed a definitive license agreement for rights to Teewinot Life Sciences Corp.'s patented biosynthetic technology to produce NEMUS' proprietary cannabinoid molecules.

"Nemus is anticipating an era of hypergrowth in the pharmaceuticalized cannabinoid space and we believe that the biosynthetic technology that Teewinot has developed fits with our industry-disruptive approach to this therapeutic market," commented Brian Murphy, M.D., M.B.A., CEO and Chief Medical Officer of Nemus. "We believe that the use of standard cannabinoid molecules like tetrahydrocannabinol (THC) and cannabidiol (CBD) can be improved upon using re-engineered proprietary forms of the molecules to enhance physicochemical characteristics, resulting in improved activity and safety in a business model not solely dependent on orphan drug applications. We anticipate that the biosynthetic technology being advanced by Teewinot will provide API that is more cost-effective to produce than pure chemical synthesis or deriving the molecules from plants."

Jeffrey Korentur, CEO of Teewinot Life Sciences Corporation, stated, "Our wholly owned subsidiary, Full Spectrum Laboratories, Ltd., is working to bring disruptive technologies to the area of cannabinoid manufacturing. The Teewinot team is working with Albany Molecular Research, Inc. (NASDAQ:AMRI) to advance the scale-up of biosynthetically produced products, and AMRI already has a relationship with Nemus related to API manufacturing. Our patented biocatalytic production methods and equipment offer the potential to improve not only purity and variety, but also the speed and cost of producing cannabinoid molecules over traditional botanical extraction or chemical synthesis methods."

"Nemus looks forward to the versatility of biosynthetic manufacturing to help us manufacture other cannabinoids we are currently studying for indications such as pain management and anti-infectives, especially related to resistant bacterial infections like methicillin-resistant Staphylococcus aureus (MRSA)," reported Dr. Murphy.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including statements about the timing of our near term, intermediate term and long term goals. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "could," "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

ABOUT NEMUS BIOSCIENCE, INC.

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS' strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit http://www.nemusbioscience.com.

About Teewinot Life Sciences Corporation

Teewinot Life Sciences Corporation is an international biopharmaceutical company focused on the use of synthetic biology, biocatalysis, and advanced formulation for the production and implementation of cannabinoid based therapies. With headquarters in Tampa, Florida, Teewinot manufactures and licenses technology to make cost effective, pharmaceutically pure authentic cannabinoids as an industry leader in support of advancing medical research and product development. Teewinot's global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid based medicines. For more information, please visit www.tlscorp.com or follow us on Twitter (@teewinot_corp).

CONTACTS:

NEMUS Investor Relations

PCG Advisory Group

Adam Holdsworth

Email: [e-mail]

Phone: [phone]
NEMUS Media Relations

Janet Vasquez

JV Public Relations

Email: [e-mail]

Phone: [phone]
Teewinot Media Relations

Drew White

Email: [e-mail]

Phone: [phone]
SOURCE: NEMUS Bioscience, Inc.

http://www.accesswire.com/img.ashx?id=451385